Abbott Labs (NYSE:ABT) has always been a little different as a medical technology company, with a history of zigging when other companies zag. For now, that somewhat contrarian philosophy is paying off, as Abbott is one of the very few large-cap medical technology companies to be showing any meaningful growth.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

The Quarter That Was
Abbott came through with 12% revenue growth in the third quarter (or 13% if foreign currency effects are reversed). Pharmaceuticals is still overwhelmingly the largest business at Abbott, and this unit grew more than 23% due in large part to the acquisition of Solvay. Without this deal, growth was probably in the very low single-digits. Elsewhere, the nutritional business was disappointing (down more than 2%) due to a recall, while the diagnostics business was basically on target (up about 2%), and the vascular business was strong (up almost 20%).

On an adjusted basis, the company also delivered strong profitability. Gross margin (again, adjusted) rose 4.5 points to almost 62%, while adjusted earnings grew about 14% for the quarter.

The Road Ahead
Abbott has spent a lot of its history as a med-tech chameleon - often a just a bit below the radar of most investors and willing to change its business model in anticipation of future market developments. For instance, the analyst community was not necessarily overjoyed about the company's decision to expand into drug-coated stents years ago, but now Abbott is the player with all of the momentum in that lucrative niche, and Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are on their heels. Likewise, while Beckman Coulter (NYSE:BEC), Roche (Nasdaq:RHHBY) and Becton Dickinson (NYSE:BDX) are all involved in molecular diagnostics, Abbott may steal the march on them.

Looking ahead, it would seem that Abbott is where it needs to be with its pharmaceutical business. The company has established a foothold in generics, following the lead of major players like Novartis (NYSE:NVS), and has a solid emerging pipeline in oncology and neurology. So while there is some threat to the company's immunology business from Pfizer (NYSE:PFE) and Incyte (Nasdaq:INCY), Abbott does not seem to need to do a deal - and given the FDA's attitude to new drug approvals, Abbott might be better-shielded from competitors than the market expects. (For more, see Top-Heavy Pharmaceuticals.)

If Abbott needs to do anything, it may be in the diagnostics and device franchises. An acquisition or two (like, say, of Cepheid (Nasdaq:CPHD)) could accelerate the development time lines, and the company has the luxury of cherry-picking promising areas of medical devices for future growth.

The Bottom Line
Although Abbott's stock is closer to its high than its low, the stock has actually been an underperformer relative to the S&P 500. As a strong candidate for best-of-breed within healthcare, though, it could be due for some appreciation. The stock is not necessarily cheap by fundamental indicators like EV/revenue or EV/EBITDA (or P/E-based metrics), but looks about 30% undervalued by cash flow. Abbott's stock is not likely to ever be scintillating, and the company will make moves that leave people scratching their heads in the short term, but this could be a long-term winner for patient investors. (For more, see The Characteristics Of A Successful Company.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  2. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  3. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  4. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  5. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  6. Investing

    A Look at 6 Leading Female Value Investors

    In an industry still largely predominated by men, we look at 6 leading female value investors working today.
  7. Term

    What Is Financial Performance?

    Financial performance measures a firm’s ability to generate profits through the use of its assets.
  8. Stock Analysis

    Top 3 Stocks for the Coming Holiday Season

    If you want to buck the bear market trend by going long on consumer stocks, these three might be your best bets.
  9. Investing News

    Could a Rate Hike Send Stocks Higher?

    A rate hike would certainly alter the investment scene, but would it be for the better or worse?
  10. Stock Analysis

    The Biggest Risks of Investing in FireEye Stock

    Examine the current state of FireEye, Inc., and learn about some of the biggest risks of investing in this cybersecurity company's stock.
  1. How do I use discounted cash flow (DCF) to value stock?

    Discounted cash flow (DCF) analysis can be a very helpful tool for analysts and investors in equity valuation. It provides ... Read Full Answer >>
  2. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  3. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  4. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  5. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  6. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!